Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation
 during surgery followed by external-beam radiation to the entire breast may kill more tumor
 cells.

 PURPOSE: Phase II trial to study the effectiveness of radiation therapy during surgery
 followed by whole-breast radiation therapy in treating women who have undergone lumpectomy
 for ductal carcinoma in situ or invasive breast cancer
OBJECTIVES:

 -  Determine the effect of intraoperative radiotherapy boost to the tumor bed on acute
 complications after lumpectomy (before whole breast irradiation) in women with ductal
 carcinoma in situ or invasive adenocarcinoma of the breast.

 -  Determine the local recurrence rates in patients treated with this regimen.

 -  Determine the cosmetic outcome in patients treated with this regimen.

 OUTLINE: Patients undergo excisional biopsy or surgery followed by an intraoperative dose of
 radiation to the tumor cavity. Postoperatively, patients undergo external beam radiotherapy
 to the entire breast 5 days a week for 5-6 weeks.

 Patients are followed at 1 month and then every 3 months for 2 years.

 PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.
DISEASE CHARACTERISTICS:

 -  Histologically confirmed ductal carcinoma in situ or invasive adenocarcinoma of the
 breast

 -  Primary tumor classified as T1, T2, or T3

 -  Candidate for breast-conserving surgery

 -  Must have undergone lumpectomy with negative margins or minimal margin involvement

 -  Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node
 biopsy or axillary lymph node dissection

 -  No evidence of metastatic disease

 -  Hormone receptor status:

 -  Not specified

 PATIENT CHARACTERISTICS:

 Age

 -  Adult

 Sex

 -  Female

 Menopausal status

 -  Not specified

 Performance status

 -  ECOG 0-2

 Life expectancy

 -  Not specified

 Hematopoietic

 -  WBC greater than 3,500/mm^3

 -  Granulocyte count greater than 1,500/mm^3

 -  Platelet count greater than 100,000/mm^3

 Hepatic

 -  Not specified

 Renal

 -  Not specified

 Other

 -  Not pregnant

 -  No other malignancies within the past 5 years except carcinoma in situ of the cervix
 or nonmelanoma skin cancer

 -  Prior contralateral breast cancer allowed if curatively treated more than 5 years
 previously

 -  No severe psychiatric or medical illness

 PRIOR CONCURRENT THERAPY:

 Biologic therapy

 -  Not specified

 Chemotherapy

 -  Not specified

 Endocrine therapy

 -  Not specified

 Radiotherapy

 -  No prior radiotherapy to the involved breast

 Surgery

 -  See Disease Characteristics